Literature DB >> 21623875

Successful cutaneous delivery of the photosensitizer silicon phthalocyanine 4 for photodynamic therapy.

M Lam1, A H Hsia, Y Liu, M Guo, A R Swick, J C Berlin, T S McCormick, M E Kenney, N L Oleinick, K D Cooper, E D Baron.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) has been shown to be effective in the treatment of malignancies of a variety of organ systems, including the lungs, bladder, gastrointestinal tract and skin. Cutaneous lesions serve as ideal targets of PDT because of the accessibility of the skin to light. To achieve optimum results, the photosensitizer must be delivered effectively into the target layers of the skin within a practical timeframe, via noninvasive methods. AIM: To determine whether topical application of a second-generation photosensitizer, silicon phthalocyanine (Pc) 4 [SiPc(OSi(CH3)2 (CH2)3 N(CH3)2)(OH)], results in effective penetration of the skin barrier.
METHODS: Penetration of Pc 4 was evaluated using standard Franz-type vertical diffusion cell experiments on surrogate materials (silicone membranes) and laser-scanning confocal microscopy of normal skin biopsy samples from human volunteers.
RESULTS: The Franz diffusion data indicate that Pc 4 formulated in an ethanol/propylene glycol solution (70/30%, v/v) can penetrate the membrane at a flux that is appreciable and relatively invariant. Using the same formulation, Pc 4 uptake could be detected in human skin via laser-scanning confocal microscopy.
CONCLUSION: After topical application, Pc 4 is absorbed into the epidermis in as little as 1 h, and the absorption increased with increasing time and dose. Pc 4 can be effectively delivered into human skin via topical application. The data also suggest that the degree of penetration is time- and dose-dependent. © The Author(s). CED
© 2011 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21623875      PMCID: PMC3140567          DOI: 10.1111/j.1365-2230.2010.03989.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  22 in total

1.  Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial.

Authors:  I Wang; N Bendsoe; C A Klinteberg; A M Enejder; S Andersson-Engels; S Svanberg; K Svanberg
Journal:  Br J Dermatol       Date:  2001-04       Impact factor: 9.302

Review 2.  The photobiology of photodynamic therapy: cellular targets and mechanisms.

Authors:  N L Oleinick; H H Evans
Journal:  Radiat Res       Date:  1998-11       Impact factor: 2.841

Review 3.  Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer.

Authors:  S H Ibbotson
Journal:  Br J Dermatol       Date:  2002-02       Impact factor: 9.302

Review 4.  An update on photodynamic therapy applications.

Authors:  Thomas J Dougherty
Journal:  J Clin Laser Med Surg       Date:  2002-02

5.  Analysis of photosensitivity in Japanese cancer-bearing patients receiving photodynamic therapy with porfimer sodium (Photofrin).

Authors:  S I Moriwaki; J Misawa; Y Yoshinari; I Yamada; M Takigawa; Y Tokura
Journal:  Photodermatol Photoimmunol Photomed       Date:  2001-10       Impact factor: 3.135

6.  Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent.

Authors:  M J Egorin; E G Zuhowski; D L Sentz; J M Dobson; P S Callery; J L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

7.  Photodynamic therapy-induced apoptosis in epidermoid carcinoma cells. Reactive oxygen species and mitochondrial inner membrane permeabilization.

Authors:  M Lam; N L Oleinick; A L Nieminen
Journal:  J Biol Chem       Date:  2001-09-28       Impact factor: 5.157

Review 8.  Photodynamic therapy in oncology.

Authors:  C H Sibata; V C Colussi; N L Oleinick; T J Kinsella
Journal:  Expert Opin Pharmacother       Date:  2001-06       Impact factor: 3.889

9.  Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate.

Authors:  S R Wiegell; J Skiveren; P A Philipsen; H C Wulf
Journal:  Br J Dermatol       Date:  2008-02-16       Impact factor: 9.302

Review 10.  Non-oncologic indications for ALA-PDT.

Authors:  R-M Szeimies; M Landthaler; S Karrer
Journal:  J Dermatolog Treat       Date:  2002       Impact factor: 3.359

View more
  7 in total

1.  Activated T cells exhibit increased uptake of silicon phthalocyanine Pc 4 and increased susceptibility to Pc 4-photodynamic therapy-mediated cell death.

Authors:  David C Soler; Jennifer Ohtola; Hideaki Sugiyama; Myriam E Rodriguez; Ling Han; Nancy L Oleinick; Minh Lam; Elma D Baron; Kevin D Cooper; Thomas S McCormick
Journal:  Photochem Photobiol Sci       Date:  2016-05-10       Impact factor: 3.982

2.  Topical photodynamic therapy using transfersomal aluminum phthalocyanine tetrasulfonate: in vitro and in vivo study.

Authors:  Kawser Kassab; Doaa Abd El Fadeel; Maha Fadel
Journal:  Lasers Med Sci       Date:  2013-01-05       Impact factor: 3.161

3.  Evaluation of Silicon Phthalocyanine 4 Photodynamic Therapy Against Human Cervical Cancer Cells In Vitro and in Mice.

Authors:  Jill A Gadzinski; Jianxia Guo; Brian J Philips; Per Basse; Ethan K Craig; Lisa Bailey; John T Comerci; Julie L Eiseman
Journal:  Adv Biol Chem       Date:  2016-12-30

4.  Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics.

Authors:  Leanne B Josefsen; Ross W Boyle
Journal:  Theranostics       Date:  2012-10-04       Impact factor: 11.556

5.  Cutaneous penetration of the topically applied photosensitizer Pc 4 as detected by intravital 2-photon laser scanning microscopy.

Authors:  Alex Y Huang; Jay T Myers; Deborah Barkauskas; Scott J Howell; Nancy L Oleinick; Thomas S McCormick; Kevin D Cooper; Elma D Baron; Minh Lam
Journal:  Photodiagnosis Photodyn Ther       Date:  2012-02-23       Impact factor: 3.631

6.  Preliminary clinical and pharmacologic investigation of photodynamic therapy with the silicon phthalocyanine photosensitizer pc 4 for primary or metastatic cutaneous cancers.

Authors:  Timothy James Kinsella; Elma D Baron; Valdir C Colussi; Kevin D Cooper; Charles L Hoppel; Stephen T Ingalls; Malcolm E Kenney; Xiaolin Li; Nancy L Oleinick; Seth R Stevens; Scot C Remick
Journal:  Front Oncol       Date:  2011-06-30       Impact factor: 6.244

Review 7.  Like a bolt from the blue: phthalocyanines in biomedical optics.

Authors:  Nawal Sekkat; Hubert van den Bergh; Tebello Nyokong; Norbert Lange
Journal:  Molecules       Date:  2011-12-23       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.